title: Tacrolimus-Induced Diabetic Ketoacidosis After Allogeneic Bone Marrow Transplant.
abstract: New-onset diabetes mellitus after solid-organ transplant makes for complicated tacrolimus immunosuppression. However, tacrolimus-associated diabetic ketoacidosis has not been reported in bone marrow transplant. We report 24-year-old women, hospitalized with diabetic ketoacidosis, 70 days after undergoing a bone marrow transplant with tacrolimus immunosuppression. Clinicians should be wary about tacrolimus levels and the risk of hyperglycemic states after bone marrow transplant as with other solid-organ transplants.
authors.affiliation: Department of Hematology, Başkent University, Adana, Turkey.
authors.forename: Soner
authors.initials: S
authors.lastname: Solmaz
authors.forename: Zafer
authors.initials: Z
authors.lastname: Gökgöz
authors.forename: Çiğdem
authors.initials: Ç
authors.lastname: Gereklioğlu
authors.forename: Mahmut
authors.initials: M
authors.lastname: Yeral
authors.forename: Can
authors.initials: C
authors.lastname: Boğa
authors.forename: Hakan
authors.initials: H
authors.lastname: Özdoğu
mesh_terms: D016026:Bone Marrow Transplantation; D065095:Calcineurin Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D016572:Cyclosporine / Q000008:administration & dosage; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D016903:Drug Monitoring; D057915:Drug Substitution; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000601:surgery*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus